---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-033157"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:17:14.078545+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TriSalus reports preliminary Q4 revenue $5.7M (+77% YoY) and FY23 revenue $18.5M (+49% YoY)

## Summary
- Preliminary Q4 2023 revenue $5.7M (up 77% vs Q4 2022); full-year 2023 revenue $18.5M (up 49% vs 2022).
- Gross margin improved to ~90% in Q4 2023 and ~86% for FY2023, vs 75% and 82% a year ago.
- Cash and equivalents $11.8M as of Dec 31, 2023; expects liquidity to fund operations into Q2 2024.
- Revenue entirely from TriNav Infusion System; final audited financials not yet released.
- Preliminary estimates are unaudited and subject to change; auditor has not performed any procedures.

## SEC filing metadata
- accession: 0001104659-24-033157
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000110465924033157/0001104659-24-033157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000110465924033157/tm248546d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-033157
- JSON: https://secwatch.observer/filing/0001104659-24-033157.json
- Plain text: https://secwatch.observer/filing/0001104659-24-033157.txt

## Key facts
- Earnings Releases
  TriSalus Life Sciences, Inc. reported fiscal year-ended December 31, 2023 results: revenue approximately $5.7 million for the fourth quarter of 2023.
  - Period: fiscal year-ended December 31, 2023
  - Revenue: approximately $5.7 million for the fourth quarter of 2023
  - Result: preliminary results
  source text: On March 11, 2024, TriSalus Life Sciences, Inc. (the “Company”) announced a preliminary unaudited financial update with respect to the Company’s fiscal year-ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465924033157/0001104659-24-033157-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.